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Original ArticleItaconate modulates tricarboxylic acid and redox
metabolism to mitigate reperfusion injuryThekla Cordes 1, Alfredo Lucas 1, Ajit S. Divakaruni 2,3, Anne N. Murphy 2, Pedro Cabrales 1,
Christian M. Metallo 1,*ABSTRACT
Objectives: Cerebral ischemia/reperfusion (IR) drives oxidative stress and injurious metabolic processes that lead to redox imbalance,
inflammation, and tissue damage. However, the key mediators of reperfusion injury remain unclear, and therefore, there is considerable interest
in therapeutically targeting metabolism and the cellular response to oxidative stress.
Methods: The objective of this study was to investigate the molecular, metabolic, and physiological impact of itaconate treatment to mitigate
reperfusion injuries in in vitro and in vivo model systems. We conducted metabolic flux and bioenergetic studies in response to exogenous
itaconate treatment in cultures of primary rat cortical neurons and astrocytes. In addition, we administered itaconate to mouse models of cerebral
reperfusion injury with ischemia or traumatic brain injury followed by hemorrhagic shock resuscitation. We quantitatively characterized the
metabolite levels, neurological behavior, markers of redox stress, leukocyte adhesion, arterial blood flow, and arteriolar diameter in the brains of
the treated/untreated mice.
Results: We demonstrate that the “immunometabolite” itaconate slowed tricarboxylic acid (TCA) cycle metabolism and buffered redox
imbalance via succinate dehydrogenase (SDH) inhibition and induction of anti-oxidative stress response in primary cultures of astrocytes and
neurons. The addition of itaconate to reperfusion fluids after mouse cerebral IR injury increased glutathione levels and reduced reactive oxygen/
nitrogen species (ROS/RNS) to improve neurological function. Plasma organic acids increased post-reperfusion injury, while administration of
itaconate normalized these metabolites. In mouse cranial window models, itaconate significantly improved hemodynamics while reducing
leukocyte adhesion. Further, itaconate supplementation increased survival in mice experiencing traumatic brain injury (TBI) and hemorrhagic
shock.
Conclusions: We hypothesize that itaconate transiently inhibits SDH to gradually “awaken” mitochondrial function upon reperfusion that
minimizes ROS and tissue damage. Collectively, our data indicate that itaconate acts as a mitochondrial regulator that controls redox metabolism
to improve physiological outcomes associated with IR injury.
 2019 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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injury1. INTRODUCTION
Brain damage and cerebral ischemic insults such as stroke and
traumatic brain injuries (TBI) limit oxygen and nutrient supplies to the
brain, which results in massive redox imbalance, tissue damage,
neuronal death, and irreversible neurological consequences. While
reperfusion is necessary for survival, it is associated with the in-
duction of oxidative stress and inflammatory responses in cells that
survive the initial ischemic insult [1,2]. These latter events markedly
exacerbate the initial depletion of oxygen and nutrients via metabolic
reprogramming, production of reactive oxygen and nitrogen species1Department of Bioengineering, University of California, San Diego, 9500 Gilman Drive,
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ever, effective therapies to address key mediators of reperfusion
injury remain elusive. De-energization results in the loss of ionic
homeostasis that, in turn, triggers the cascade of ischemia/reper-
fusion (IR) injury and inability of cellular organelles, specifically
mitochondria, to re-establish normal metabolic function that is a
primary determinant of tissue survival [7e9]. Ultimately, reperfusion
injury can drive extensive tissue damage and increase the risk of
sepsis and multiple organ failure [10e12]. As a significant unmet
medical need, there is current interest in therapeutically targeting
metabolism to improve outcomes [13,14].92093 La Jolla, CA, USA 2Department of Pharmacology, University of California, San
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Abbreviations
[Ue13C]substrate Uniformly labeled 13C carbon tracer
CAD/IRG1 Cis-aconitate decarboxylase/immunoresponsive gene 1 protein
ATF3 Activating transcription factor 3
CCA Common carotid arteries
CSF Cerebrospinal fluid
DHR-123 Dihydrorhodamine-123
DMM Dimethyl malonate
G6pd Glucose-6-phosphate dehydrogenase
Gclm Glutamate-cysteine ligase
Gpx1 Glutathione peroxidase 1
GSH Reduced glutathione
Gsr Glutathione reductase
GSSG Oxidized glutathione
Hmox1 Heme oxygenase 1
HS Hemorrhagic shock
IR Ischemia/reperfusion
KEAP1 Kelch-like ECH-associated protein 1
LR Lactated Ringer’s solution
MAP Mean arterial pressure
MCA Middle cerebral artery
NMDA N-methyl-D-aspartate
NO Nitric oxide
NOS Nitric oxide synthase
Nqo1 NAD(P)H dehydrogenase
Nrf2 Nuclear factor erythroid 2-related factor 2
PMP Plasma membrane permeabilizer
RET Reverse electron transport
RNS Reactive nitrogen species
ROS Reactive oxygen species
SDH Succinate dehydrogenase
TCA Tricarboxylic acid
TBI Traumatic brain injuryAlthough direct antioxidants have failed clinically [15], therapies to
improve survival and recovery from IR injury, such as cerebral
ischemia, stroke, and TBI, must directly or indirectly reduce oxidative
stress, which is characterized by an imbalance between ROS gener-
ation and anti-oxidant defense systems. Succinate dehydrogenase
(SDH) activity drives a significant portion of ROS generation, and it has
been demonstrated that SDH inhibition by malonate is protective
against reperfusion injuries [5]. Notably, itaconate inhibits SDH in a
dose-dependent manner, leading to succinate accumulation [16,17].
Itaconate is synthesized de novo in myeloid cells by decarboxylation of
the tricarboxylic acid (TCA) cycle intermediate cis-aconitate via the
enzyme cis-aconitate decarboxylase/immunoresponsive gene 1 pro-
tein (CAD/IRG1), which is highly expressed under pro-inflammatory
conditions [18e21]. Although macrophages produce endogenous
itaconate at mM levels [16,18,22], this metabolite is secreted at low
rates and is not detectable at high concentrations in humans with
acute inflammation or sepsis [23]. We therefore hypothesized that
itaconate could serve as a stable degradable inhibitor of SDH to
attenuate ROS production from the electron transport chain during
reperfusion.
In addition, an anti-inflammatory role for synthetic cell-permeable
derivatives of itaconate has been described, where itaconyl esters
alkylate cysteine residues on the Kelch-like ECH-associated protein 1
(KEAP1), enabling stabilization of nuclear factor erythroid 2-related
factor 2 (Nrf2) and also induce activating transcription factor 3
(ATF3)-dependent pathways [24,25]. Importantly, Nrf2 activation in-
duces the expression of ROS scavenging enzymes, anti-inflammatory,
and cytoprotective genes that limit oxidative damage triggered by
ischemia and brain injury [26,27].
Little is known about the impact of exogenous itaconate on meta-
bolism, redox stress, and ischemic damage. In this study, we inves-
tigated the metabolic and physiological effects of itaconate treatment
in cultured cortical neurons and astrocytes as well as on mouse
models of cerebral reperfusion injury. We hypothesize that the
administration of itaconate preserves metabolic function, thereby
reducing cellular damage upon ischemic insults. Specifically, we
observed that itaconate treatment inhibits SDH and promotes gene
expression associated with anti-oxidant pathways. When administered
prior to reperfusion in mouse models of cerebral ischemia and TBI with
hemorrhagic shock (HS), itaconate reduced oxidative stress and
improved cerebral hemodynamics, inflammation, neurologicalMOLECULAR METABOLISM 32 (2020) 122e135  2019 The Authors. Published by Elsevier GmbH. This is an open
www.molecularmetabolism.comfunction, and survival. These results provide evidence that itaconate
mitigates pathology associated with reperfusion injury.
2. MATERIALS AND METHODS
2.1. Study approval
Animal handling and care was approved by the Institutional Animal
Care and Use Committee of the University of California, San Diego, CA,
and was conducted accordingly to the Guide for the Care and Use of
Laboratory Animals (US National Research Council, 2010). C57BL/6J
mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA).
2.2. Animal model of cerebral ischemia reperfusion
Acute cerebral ischemia was achieved by placing two micro clips in
tandem on the left middle cerebral artery (MCA) at 1 mm proximal to
the MCA bifurcation but distal to the origin of the lenticulostriate ar-
teries. This was immediately followed by the ligation of the bilateral
common carotid arteries (CCA). For occlusion reperfusion, the clips and
CCA ligations were removed 60 min after the start of occlusion,
respectively. During the experiment, both brain and rectal tempera-
tures were maintained at approximately 37 C with an external heating
pad. Temperatures and blood pressure were continuously monitored.
Arterial blood gases were examined at pre-occlusion and 120 min after
the start of occlusion. Itaconate was infused for 30 min at 15 mg/kg/
min prior to ligation, stopped during ligation, and infused again for
30 min during reperfusion. Itaconate was dissolved in 0.9% NaCl
solution (Hospira Inc.) and adjusted to pH ¼ 7.2. A vehicle group was
infused with 0.9% NaCl. A sham group underwent surgery but without
ligation. Male mice aged nine weeks were used to study ischemia
reperfusion.
2.3. Animal model of traumatic brain injury (TBI) followed by
hemorrhagic shock (HS)
The mice were subjected to fluid percussion TBI followed by hemor-
rhage of 50% of the animal’s blood volume. Thirty min after the
trauma, volume fluid resuscitation was accomplished according to the
Tactical Combat Casualty Care (TCCC) field care guidelines, preserving
the mean arterial pressure (MAP) above 70 mmHg for 4 h. Fluid
resuscitation was accomplished using lactated Ringer’s solution (LR),
Hextend (6% Hetastarch in Lactated Electrolyte Injection, Hospira Inc.,
Lake Forest, IL, USA), or Hextend with 15 mg/mL of itaconate. Theaccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 123
Original Articleitaconate solution was adjusted to pH ¼ 7.2. After 4 h, the mice were
placed in their cages with free access to food and water for 7 days (all
groups with n ¼ 6). The mean arterial blood pressure (MAP) was
measured on a temperature-controlled platform. Male mice aged nine
weeks were used to study TBI/HS.
2.4. Glutathione measurements
Total glutathione as well as reduced (GSH) and oxidized glutathione
(GSSG) in the brain tissue were measured using enzyme-linked assay
kits (Cayman Chemical, Ann Arbor, MI, USA). The brain was removed,
weighed and one of the hemispheres was processed for the mea-
surement of total glutathione (GSH þ GSSG) and GSSG. The brain
sample was homogenized in 5 mL of cold buffer per gram of tissue
using a T25 basic electric homogenizer. The precipitate was removed
by centrifugation and the supernatant was collected and frozen until
assaying.
2.5. Neurological function (motor score)
After the ischemic insult, the mice were subjected to a series of
neurologic tests designed to detect motor deficits [28]. Briefly, the
mice were placed on a rotating 15  15 cm screen (grid size
0.2 0.2 cm). The duration of time that the mouse could hold onto the
screen after it was rotated from horizontal to vertical was recorded.
Next, the amount of time that the mouse could remain balanced on a
horizontal board was recorded. Finally, the mouse underwent a pre-
hensile traction test by timing up to 5 s the period that the mouse could
cling to a horizontal rope. Using these three tests, a maximal score of
25 and a minimal score of 0 was obtained.
2.6. Cerebral reactive oxygen/nitrogen species (ROS/RNS)
Oxidant-sensitive dihydrorhodamine-123 (DHR-123, Molecular Probes
Inc., 20 mmol/L) was used to quantify the oxidant production in the
cerebral venules following ischemia reperfusion [29]. Briefly, the DHR-
123 was dissolved in artificial cerebrospinal fluid (CSF) and super
fused on the brain surface of the closed cranial window. The brain
tissue was exposed to the DHR for 15 min, followed by suffusion with
plain artificial CSF. DHR oxidation was visualized and quantified. DHR
fluorescence intensity was monitored in a region of the brain surface
that was equivalent to twice the area of the venular segment under
study and in a rectangular area immediately outside the vessels.
2.7. Mice cranial window model
The closed cranial window model was implanted in mice anes-
thetized with ketamine-xylazine. The mice were first administered
dexamethasone (0.2 mg/kg), carprofen (5 mg/kg), and ampicillin
(6 mg/kg) subcutaneously to prevent swelling of the brain, inflam-
matory response, and infection. After shaving the head and cleansing
with ethanol 70% and betadine, the mouse was placed on a ste-
reotaxic frame and the head immobilized using ear bars. The scalp
was removed with sterilized surgical instruments, and lidocaine-
epinephrine was applied on the periosteum, which was then
retracted, exposing the skull. A 3- to 4-mm-diameter skull opening
was made in the left parietal bone using a surgical drill. Under a
saline drip, the craniotomy was lifted away from the skull with very
thin tip forceps and Gelfoam previously soaked in saline was applied
to the dura mater to stop any eventual minor bleeding. The exposed
area was covered with a 5 mm glass coverslip secured with
cyanoacrylate-based glue and dental acrylic. Carprofen and ampi-
cillin were administered daily for three to five days after recovery
from surgery. One week after surgery, the mice were lightly anes-
thetized with isoflurane to complete the ischemic model. A124 MOLECULAR METABOLISM 32 (2020) 122e135  2019 The Authors. Published by Elsevier GmbH. Tpanoramic picture of the vessels under the window was taken, and
then mice were transferred to an intravital microscope stage
(customized Leica-McBain, San Diego, CA, USA). Body temperature
was maintained using a heating pad. Using water-immersion ob-
jectives ( 20), blood vessel images were captured (Cohu 4815,
Cohu, Inc., San Diego, CA, USA) and recorded on videotape. An image
shear device (Image Shear, Vista Electronics, San Diego, CA, USA)
was used to measure the baseline vessel diameters (D), and the RBC
velocities (V) were measured offline by cross-correlation (Photo
Diode/Velocity Tracker Model 102B, Vista Electronics, San Diego, CA,
USA). Measurements of the pial arterioles (diameter range: <20 mm
(small vessels), 21e50 mm (medium vessels), and 51e100 mm
(large vessels), each n ¼ 14e15) were performed in each animal,
and the blood flow (Q) in each individual vessel was calculated using
the equation: Q ¼ V p(D/2)2. Adherent and rolling leukocytes were
visualized by anti-CD45-TxR antibodies (Caltag, Carlsbad, CA, USA)
and infused via i.v. Green fluorescence (518 nm) emitted by albumin-
FITC and GFP (PbA-GFP pRBC) was captured using ALPHA Vivid:
XF100-2 (Omega Optical, Brattleboro, VT, USA), and anti-CD45-TxR
fluorescence (615 nm) was exited and captured with a Vivid Stan-
dard XF42.
2.8. Primary cortical neurons and astrocytes
Primary cortical neurons and astrocytes were generated from em-
bryonic day 18 SpragueeDawley rats as previously described [30,31].
Briefly, cortical neurons were plated onto poly-D-lysine-coated wells of
96-well Seahorse XFe96 plates (2.5  104 cells/well) or 12-well
dishes (1  105 cells/well) and maintained at 37 C in a humidified
incubator with 5% CO2. The cells were maintained in maintenance
medium composed of neurobasal medium (Thermo Fisher Scientific)
supplemented with 1 B27 of serum-free supplement (Thermo Fisher
Scientific), 2 mM of GlutaMAX (Thermo Fisher Scientific), 100 U/ml of
penicillin, and 100 mg/ml of streptomycin. Half of the medium was
replaced every 3e4 days. The experiments were conducted on day
in vitro (DIV) 19e21. Cortical astrocytes were prepared according to
[32] and plated onto 12-well culture plates (1  105 cells/well). Pri-
mary astrocytes were cultivated in DMEM (SigmaeAldrich, D5030)
supplemented with 10% FBS, 100 U/ml of penicillin, 100 mg/ml of
streptomycin, 10 mM of glucose, and 0.5 mM of glutamine.
2.9. Isotopic tracing
For isotopic labeling experiments, primary neurons were cultured in
custom Neuro-c medium as previously described in detail [31]. For
tracing studies, 12C glucose was replaced with 8 mM of [Ue13C6]
glucose (Cambridge Isotopes, CLM-1396), 12C leucine was replaced
with 0.8 mM of [Ue13C6]leucine (Cambridge Isotopes, CLM2-2262), or
2 mM of [Ue13C4]b-hydroxybutyrate (SigmaeAldrich 606030) was
supplemented to the medium. For tracing with labeled glutamine, Glu-
taMAX was omitted and replaced with 0.5 mM of [Ue13C5]glutamine
(Cambridge Isotopes, CLM-1822) and N-methyl-D-aspartate (NMDA)
receptor antagonist MK801 (10 mM) was added to prevent excitotoxic
neuronal injury. Primary astrocytes were cultured in DMEM medium
(SigmaeAldrich, D5030) containing 10 mM of glucose, 10% FBS, 100
U/ml of penicillin, 100 mg/ml of streptomycin, and 0.5 mM of [Ue13C5]
glutamine. The cells were cultured in medium containing stable isotope
tracers of choice as indicated in the text. For itaconate degradation
studies, primary cortical neurons were exposed to 2 mM and primary
astrocytes to 1 mM of exogenous [Ue13C5]itaconate for 48 h (NIH
Metabolite Standards Synthesis Core). The cultured cells were exposed
to 2 mM of exogenous itaconate (SigmaeAldrich, Cat. No. I29204) as
indicated in the text. All of the media were adjusted to pH ¼ 7.3.his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Mass isotopomer distributions and total metabolite abundances were
computed by the integration of mass fragments using a MATLAB-
based INCA algorithm with corrections for natural isotope abun-
dances as previously described [33]. Labeling was depicted as the
isotopologue distribution or 13C incorporation into metabolite (mole
percent enrichment) [34].
2.10. Gas chromatograph-mass spectrometry (GCeMS), sample
preparation, and analysis
The metabolites were extracted, analyzed, and quantified as previously
described in detail by Cordes and Metallo [34]. Briefly, the cells were
washed with saline solution and quenched with 0.25 ml of 20 C
methanol. After adding 0.1 ml of 4 C water, the cells were collected in
tubes containing 0.25 ml of 20 C chloroform. Plasma metabolites
were extracted using 5 ml of plasma, 0.25 ml of 20 C methanol,
0.1 ml of 4 C cold water, and 0.25 ml of 20 C chloroform. The
extracts were vortexed for 10 min at 4 C and centrifuged at 16,000
g for 5 min at 4 C. The upper aqueous phase was evaporated under a
vacuum at 4 C. Derivatization for polar metabolites was performed
using a Gerstel MPS with 15 ml of 2% (w/v) methoxyamine hydro-
chloride (Thermo Scientific) in pyridine (incubated for 60 min at 45 C)
and 15 ml of N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide
(MTBSTFA) with 1% tert-butyldimethylchlorosilane (Regis Technolo-
gies) and incubated further for 30 min at 45 C. Derivatives were
analyzed by GCeMS using a DB-35MS column (30 m x 0.25 i.d. x
0.25 mm) installed in an Agilent 7890B gas chromatograph (GC)
interfaced with an Agilent 5977A mass spectrometer (MS) operating
under electron impact ionization at 70 eV. The MS source was
maintained at 230 C and the quadrupole at 150 C and helium was
used as a carrier gas. The GC oven was maintained at 100 C for
2 min, increased to 300 C at 10 C/min and maintained for 4 min, and
maintained at 325 C for 3 min.
2.11. Respirometry
Respiration was measured in adherent monolayers of primary neurons
using a Seahorse XFe96 Analyzer with a minimum of 6 biological
replicates per plate as previously described [31]. Intact cells were
assayed in custom neurobasal medium (ScienCell) supplemented with
5 mM of HEPES, 8 mM of glucose, and 1 mM of pyruvate. Respiration
was measured under basal conditions as well as after injection of 2 mM
of oligomycin (Oligo), sequential additions of 300 nM of FCCP, and the
addition of 0.5 mM of rotenone and 1 mM of antimycin (Ant/Rot). The
medium contained 0 mM or 2 mM of itaconate and the pH was
adjusted to pH ¼ 7.3 using NaOH. Neurons were incubated in the
assay medium for 15 min before starting the assay.
To measure the respiration on specific respiratory substrates, cells
were permeabilized with 3 nM of recombinant perfringolysin O (rPFO,
commercial XF plasma membrane permeabilizer (PMP), Agilent
Technologies) as previously described [35]. Permeabilized neurons
were offered oxidizable substrates plus 4 mM of ADP and the initial
oxygen consumption was measured, followed by injection of 2 mM of
oligomycin (Oligo), sequential additions of 2 mM of FCCP and then the
addition of 0.5 mM of rotenone and 1 mM of antimycin (Ant/Rot).
Permeabilized neurons were offered 10 mM of succinate with 2 mM of
rotenone (Suc/Rot), 5 mM of pyruvate with 1 mM of malate (Pyr/Mal) or
10 mM of ascorbate with 100 mM of TMPD and 1 mM of antimycin A
(Asc/TMPD). Maximal respiration was calculated as the difference
between protonophore-stimulated respiration (4 mM of FCCP) and non-
mitochondrial respiration (measured after the addition of 1 mM of
antimycin A and 0.5 mM of rotenone). All of the media were adjusted to
pH ¼ 7.3 using KOH.MOLECULAR METABOLISM 32 (2020) 122e135  2019 The Authors. Published by Elsevier GmbH. This is an open
www.molecularmetabolism.com2.12. RNA isolation and quantitative RT-PCR analysis
Total RNA was purified from cultured cells using a Qiagen RNeasy Mini
Kit (Qiagen) per the manufacturer’s instructions. First-strand cDNA was
synthesized from total RNA using iScript Reverse Transcription Supermix
for RT-PCR (Bio-Rad Laboratories) according to the manufacturer’s in-
structions. Individual 10 ml SYBR Green real-time PCR reactions con-
sisted of 1 ml of diluted cDNA, 5 ml of fast SYBR Green Master Mix
(Applied Biosystems), and 0.25 ml each of 10 mM forward and reverse
primers. To standardize the quantification, b-actin was amplified
simultaneously. PCR was carried out in 96-well plates on an Applied
Biosystems ViiA 7 Real-Time PCR System using the following parame-
ters: 95 C for 20 s, 40 cycles of 95 C for 1 s, and 60 C for 20 s.
Slc7a11 (forward CCCAGATATGCATCGTCCTT, reverse ACAACCAT-
GAAGAGGCAGGT), Hmox1 (forward TGACAGAGGAACACAAAGACC,
reverse TGAGTGTGAGGACCCATCG), Gclm (forward CTGCTAAACTGTT-
CATTGTAGG, reverse CTATGGGTTTTACCTGTG), Gsr (forward
CCATGTGGTTACTGCACTTC, reverse CTGAAGCATCTCATCGCAG), Gpx1
(forward TTGAGAATGTCGCGTCC, reverse AAGCCCAGATACCAGGA),
Nqo1 (forward TGCTTTCAGTTTTCGCCTTT, reverse GAGGCCCC-
TAATCTGACCTC), G6pd (forward GCCTTCTACCCGAAGACACCTT,
reverse CTGTTTGCGGATGTCATCCA), beta-actin (forward CGCGAGTA-
CAACCTTCTTGC, reverse CGTCATCCATGGCGAACTGG).
2.13. Immunoblotting
Cells were lysed in ice-cold RIPA buffer supplemented with 1x HALT
protease inhibitor cocktail (Thermo Fisher Scientific, Cat. No. 78430). A
BCA assay was used to determine the protein concentrations. Overall,
20 mg of total protein was separated on a 4e20% SDS-PAGE gel
(mini-protean TGX gels, Bio-Rad) and the proteins were transferred
onto a PVDF membrane (Millipore, Cat. No. IPVH10100). The mem-
brane was blocked with 5% non-fat milk in tris-buffered saline with
0.1% Tween 20 (TBS-T) for 1 h and immunoblotted with primary
antibody at 4 C overnight diluted in 5% non-fat milk. Anti-NRF2
(1:1000 dilution, Abcam, Cat. No. ab137550), anti-Hmox1 (1:1000
dilution, Cell Signaling Technology, Cat. No. E6Z5G), and anti-beta-
actin (1:1000 dilution, Cell Signaling Technology, Cat. No. 4970).
The immunoblots were then incubated with secondary antibody for
1 h at room temperature (Monoclonal anti-rabbit antibody HRP-con-
jugate, Cell Signaling Technology, Cat. No 7074, 1:10,000 dilution).
Specific signaling was detected using SuperSignal West Pico Chemi-
luminescent Substrate (Bio-Rad, Cat. No. 1705061) and imaged with a
Bio-Rad ChemiDoc XRS þ imaging station. Band signaling from
Western blotting was determined using ImageJ software and
normalized to beta-actin signaling.
2.14. Statistics
Statistical analysis was performed using GraphPad Prism 7. The type
and number of replicates and the statistical test used are described in
the figure legends. Data are presented as means s.e.m. or box (25th
to 75th percentile with median line) and whiskers (min. to max. values)
as described in the figure legends. A tissue culture was conducted in
12-well tissue culture plates, with each well considered one biological
replicate for a given preparation of neurons or astrocytes (minimum of
3 wells per condition). Seahorse assays were performed in 96-well
plates, with each well considered a biological replicate (minimum of
6 wells per condition). The mRNA expression was detected with three
biological replicates (each with two technical replicates). The protein
expression was depicted for three biological replicates. All the data
were depicted from one representative experiment and each experi-
ment was repeated one or more times with the exception of the res-
piratory assay in Figures 1C and 2D as specified in each figure legend.access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 125
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Figure 1: Itaconate inhibited SDH activity in primary cortical neurons. A) Intracellular itaconate levels increased after exposure to 2 mM exogenous itaconate for 2 h. B)
Exogenous itaconate drove succinate accumulation while the other metabolites were not affected. Cells were exposed to 2 mM of exogenous itaconate for 2 h. C) Oxygen
consumption rate in primary cortical neurons exposed to 2 mM itaconate significantly decreased compared to untreated cells. D) Succinate driven respiration (complex II) in
permeabilized primary cortical neurons administered 5 mM succinate and 0.5 mM rotenone. Addition of 5 mM itaconate decreased the oxygen consumption rate. E) Schematic
depicting itaconate as a metabolic inhibitor for succinate dehydrogenase (SDH) regulating ROS production upon reperfusion. Data are represented as box (25th to 75th percentile
with median line) and whiskers (min. to max. values) with three (A and B) or means  s.e.m. with 6 biological replicates (C and D). All of the experiments were repeated three
independent times with similar results, with the exception of C, which was performed once with 6 biological replicates. Student’s t-test with ****P < 0.0001.
Original ArticleIn vivo studies were conducted with n ¼ number of male mice aged 9
weeks as indicated in each figure legend. No statistical method was
used to predetermine the sample size. P values were calculated using
Student’s two-tailed t-test, one-way ANOVA, or two-way ANOVA with a
*P value < 0.05, **P value < 0.01, and ***P value < 0.001,
respectively.
3. RESULTS
3.1. Itaconate inhibits SDH activity in primary cortical neurons
To investigate the biochemical mechanisms by which exogenous
itaconate impacts cerebral metabolism, we used primary cultures of126 MOLECULAR METABOLISM 32 (2020) 122e135  2019 The Authors. Published by Elsevier GmbH. Trat cortical neurons as a model system. We and others previously
demonstrated that extracellular itaconate modulates intracellular
metabolism in mammalian cells, including adipocytes, immune cells,
and cancer cells [16,17,25,36]. In this study, we supplemented 2 mM
of itaconate to cultures of primary cortical neurons for 2 h and
quantified the intracellular metabolite levels. Exposure to exogenous
itaconate significantly increased the intracellular levels, suggesting
that primary cortical neurons took up itaconate from the medium
(Figure 1A). Notably, itaconate elevated the intracellular succinate
levels by 5-fold, while other metabolites were not affected during this
time (Figure 1B). Further, the itaconate and succinate levels increasedhis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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suggesting that itaconate drove the observed increase in succinate in
the neuronal cultures.
We next assessed whether itaconate impairs the activity of SDH in
neurons that may be beneficial for mitigating reperfusion injuries. SDH
activity induces reverse electron transport (RET) and ROS production
upon reperfusion to promote oxidative stress and cellular injuries [5].
Since SDH (complex II of the electron transport chain) activity helps
drive mitochondrial oxygen consumption, we quantified how itaconate
impacts neuronal respiration. As depicted in Figure 1C, acute exposure
to itaconate decreased uncoupler-stimulated respiration rates in intact
primary neurons. In addition, itaconate significantly decreased
succinate-driven respiration by complex II (SDH) in permeabilizedMOLECULAR METABOLISM 32 (2020) 122e135  2019 The Authors. Published by Elsevier GmbH. This is an open
www.molecularmetabolism.comprimary cortical neurons (Figure 1D), while respiration on pyruvate/
malate (dependent on complexes I, III, and IV) and ascorbate/TMPD
(complex IV) were unaffected (Figure S1D and E). These data indicate
that exogenous itaconate specifically inhibits SDH activity and pro-
motes the accumulation of succinate in cultured primary cortical
neurons. Thus, itaconate may control the reintroduction of electrons
into the mitochondrial electron transport chain upon reperfusion
buffering ROS production and metabolic damage (Figure 1E).
3.2. Itaconate promotes glutamine metabolism
The results of this study suggest that itaconate has a direct impact on
TCA cycle metabolism. To better understand the long-term impact of
itaconate treatment, we exposed cultured neurons to exogenousaccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 127
Original Articleitaconate for 48 h. While itaconate significantly increased the intracel-
lular levels of succinate, a-ketoglutarate, and glutamate, there was a
significant decrease in the other TCA cycle and glycolytic intermediates,
including pyruvate, citrate, and malate (Figure 2A). Notably, we did not
detect any 13C labeling on the succinate or other TCA intermediate
metabolites in primary neurons exposed to uniformly (U) labeled [Ue
13C5]itaconate, indicating that cells do not catabolize itaconate appre-
ciably under these conditions (Figure 2B). Further, itaconate in culture
medium was not depleted after 48 h (Figure S2A). Our data indicate that
itaconate causes an accumulation of metabolites downstream of
glutamine, presumably due to SDH inhibition (Figure 1D).
To study itaconate-induced metabolic changes in greater detail, we
cultured cortical neurons in the presence of 13C isotope tracers and
quantified the isotope enrichment throughout the metabolome. We
cultured primary cortical neurons in custom Neurobasal-C medium
lacking specific substrates to enable replacement with isotopic labeled
tracers such as [Ue13C6]glucose, [Ue
13C5]glutamine, [Ue
13C4]b-
hydroxybutyrate, and [Ue13C6]leucine. Each of these substrates was
significantly oxidized by the primary cortical neurons [31]. For gluta-
mine tracer studies, we included the N-methyl-D-aspartate (NMDA)
receptor antagonist MK801 to prevent excitotoxic neuronal injury from
glutamine deamination [31]. While carbons derived from b-hydrox-
ybutyrate, leucine, and glucose enter the TCA cycle primarily via
acetyl-CoA, glutamine is converted into glutamate that is further
metabolized to a-ketoglutarate (Figure 2C). To compare substrate
utilization across different carbon sources, we cultured primary neu-
rons in 13C tracer medium supplemented with 0 mM or 2 mM of
itaconate for 48 h and quantified labeling on citrate. Exogenous itac-
onate significantly decreased neuronal glucose oxidation while
increasing oxidative glutamine metabolism (Figure 2D). We also
observed decreased 13C incorporation into the citrate from 13C labeled
leucine and b-hydroxybutyrate, evidence that itaconate influences
mitochondrial substrate utilization (Figure 2D).
Acute (2 h) exposure to itaconate significantly increased labeling on
succinate from [Ue13C5]glutamine while
13C incorporation into the
other TCA cycle intermediates was not affected (Figure S2B and C).
However, long-term exposure to itaconate significantly increased
isotope enrichment on the other TCA cycle intermediates and related
amino acids from [Ue13C5]glutamine (Figure 2E and Figure S2D-H)
while decreasing glucose oxidation (Figure S2I), presumably due to the
slow progressing oxidation of glutamine-derived succinate that
occurred during this prolonged time period.
Because the brain comprised of diverse cells with distinct metabolic
phenotypes, we also quantified the impact of exogenous itaconate on
primary rat cortical astrocytes. Similar to neuronal cultures, itaconate
was not catabolized into the TCA cycle intermediates (Figure S2J) but did
promote succinate accumulation (Figure 2F) and glutamine flux to
succinate (Figure 2G and S2K) in cultured astrocytes after 48 h of cul-
ture. While itaconate treatment increased the succinate levels in the
astrocytes, the other TCA cycle intermediates were not affected, sug-
gesting that distinct metabolic reprograming occurred in the astrocytes
and neurons. Collectively, our data indicate that itaconate reprograms
intermediary metabolism, specifically glutamine metabolism, in primary
cortical neurons and astrocytes, which may be beneficial for improving
metabolic homeostasis in ischemia reperfusion.
3.3. Activation of anti-oxidant cell response via itaconate in primary
brain cells
Based on this study’s metabolic data, we hypothesized that itaconate
promotes glutamine metabolism for anti-oxidant defense pathways.
Synthetic, cell-permeable derivatives of itaconate (that is, octyl-128 MOLECULAR METABOLISM 32 (2020) 122e135  2019 The Authors. Published by Elsevier GmbH. Titaconate and dimethyl-itaconate) can buffer inflammation and redox
homeostasis in immune cells via Nrf2 and ATF3 [24,25]. Nrf2 is a
transcription factor and key regulator of redox homeostasis that pro-
tects from oxidative stresses by stimulating the expression of genes
involved in heme metabolism (heme-oxygenase-1 (Hmox1)) and ROS
detoxification (NAD(P)H dehydrogenase (Nqo1)). In addition, Nrf2
contributes to cellular metabolic activities and drives the transcription
of metabolic genes advantageous for proliferation and survival [37]. In
fact, Nrf2 target genes encode numerous enzymes involved in gluta-
mine and glutathione metabolism, including glutathione peroxidase 1
(Gpx1) [38e41].
Since anti-oxidant responses are critical for mitigating reperfusion
injury [27,42], we next determined whether itaconate activates the
anti-oxidant related gene signaling pathway in primary cortical neurons
or astrocytes. To assess this, we quantified the expression of redox-
associated genes in our cell model of primary cultured brain cells in
response to itaconate treatment. In neuronal cultures, exogenous
itaconate significantly increased the expression levels of genes
associated with redox metabolism, specifically Hmox1 (3.3-fold in-
crease), Nqo1 (4.5-fold increase), and Gpx1 (2-fold increase)
(Figure 3A). Further, itaconate increased the protein levels of NRF2 by
1.5-fold and HMOX1 by 1.6-fold (Figure 3B,C). However, the expres-
sion of these genes was not dramatically affected in the primary as-
trocytes (Figure 3D). Furthermore, some classical Nrf2 targets such as
glucose-6-phosphate dehydrogenase (G6pd) were not upregulated in
the neurons (Figure 3A,D), suggesting that the transcriptional response
of neurons/astrocytes to itaconate is distinct from that occurring in
immune cells [24,25]. Collectively, we observed changes in the redox-
associated pathways in the cultured neurons, suggesting that itaconate
strongly influences glutamine metabolism that is critical for anti-
oxidant defense mechanisms (Figure 3E).
3.4. Itaconate modulates brain redox metabolism in a cerebral
ischemia-reperfusion model
Given its influence on SDH activity, glutamine metabolism, and anti-
oxidant pathway induction, we hypothesized that the administration
of itaconate prior to reperfusion might have protective effects in animal
models of cerebral ischemia. To explore this, we infused mice with
itaconate (15 mg/kg/min) for 30 min prior to inducing ischemia via
middle cerebral artery (MCA) and common carotid artery (CCA) neural
ligation and again for 30 min during reperfusion (Figure 4A). The
vehicle group was infused with 0.9% NaCl and the sham group un-
derwent surgery but without ligation. Plasma itaconate reached 2 mM
2 h after reperfusion but was not detectable in the control condition or
treated animal plasma 24 h after reperfusion, indicating that this
compound cleared rapidly in the mice (Figure 4B). We also observed
that pyruvate, lactate, TCA cycle intermediates, and amino acids were
elevated in the vehicle control groups 24 h after reperfusion compared
to baseline, suggesting that they could serve as biomarkers of
reperfusion injury [43]. Intriguingly, these metabolites were not altered
in the plasma from the itaconate-infused mice at the same time point
(Figure 4C and Figure S3A and B). These data suggest that exogenous
itaconate impacts intermediary metabolism in vivo and buffers against
metabolic alterations associated with reperfusion.
We next investigated the impact of itaconate on oxidative stress
markers after reperfusion injury. The total glutathione levels in the
brain were significantly decreased in the vehicle group compared to
the sham conditions but were not altered in the itaconate-treated
animals (Figure 4D). Reduced glutathione (GSH) is a vital protective
anti-oxidant, and the itaconate significantly elevated the GSH levels
compared to the vehicle group (Figure 4E). Further, the oxidizedhis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
BA
Cys2Gln
Glu
extracellular space
TCA cycle
Glu
SLC7A11
Glutamyl-
cysteine
Cys
GSH
(reduced)
GSSG
(oxidi zed)
H2O2
H2O
NAD(P)+
NAD(P)H
GPX GSR
G6PD
NQO1
GCL
Redox metabolismItaconate
aKG
Itaconate
Suc
Fum
Nq
o1
Hm
ox
1
Gc
lm Gs
r
Slc
7A
11
Gp
x1
G6
pd
0
2
4
6
Neurons
m
RN
A
le
ve
l
re
la
tiv
e
to
0m
M
ita
0mM ita
2mM ita*
*
**
*
C
NRF2
HMOX1
Actin
Mm2etanocatI 0mM
NRF2 HMOX1
0.0
0.5
1.0
1.5
2.0
Pr
ot
ei
n
ex
pr
es
si
on
re
la
tiv
e
to
0m
M
ita
0mM ita 2mM ita
** *
D E
Nq
o1
Hm
ox
1
Gc
lm Gs
r
Slc
7a
11
Gp
x1
G6
pd
0
1
2
3
4
5
6
Astrocytes
m
RN
A
le
ve
l
re
la
tiv
e
to
0m
M
ita
0mM ita
2mM ita
*
HMOX1
Figure 3: Itaconate induced anti-oxidant cell response in primary brain cells. A) Itaconate induced expression of anti-oxidant-related genes in primary cortical neurons. B)
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similar results. Student’s t-test with *P < 0.05 and **P < 0.01.glutathione levels (GSSG) were significantly increased in the vehicle
group but not in the itaconate group while the GSH/GSSG ratios were
significantly decreased upon itaconate treatment compared to the
sham conditions (Figure 4F,G). Our data indicate that itaconate protects
against glutathione depletion and improves the anti-oxidant capacity of
cells (Figure 4F,G). Furthermore, itaconate decreased the NADH/NADþ
ratio in the brain 2 h after reperfusion (Figure 4H), providing evidence
that oxidative metabolism is better maintained when itaconate is
administered prior to neural ligation and during reperfusion. Impor-
tantly, itaconate also reduced the cerebral ROS/RNS levels compared
to the vehicle-treated controls as measured by oxidant-sensitive
dihydrorhodamine-123 (DHR-123) fluorescent probes (Figure 4I).
These data suggest that itaconate elicits beneficial metabolic effects
when applied to in vivo models of reperfusion injury.
3.5. Itaconate improves hemodynamics and brain function after
reperfusion injury
Reperfusion injury can also compromise cerebral blood flow,
contributing to further tissue damage due to impaired oxygen and
nutrient delivery. To directly investigate the impact of itaconate on
cerebral hemodynamics and microvascular function, we used a closed
cranial window chamber that allowed us to monitor vascular function
within the brain after reperfusion in real time. Specifically, we
measured the critical microvascular parameters involved in ischemia-
reperfusion injury, that is, arteriolar diameter, blood flow, andMOLECULAR METABOLISM 32 (2020) 122e135  2019 The Authors. Published by Elsevier GmbH. This is an open
www.molecularmetabolism.comleukocyte adhesion. Itaconate prevented arteriolar vessel collapse
(Figure 5A and S4A), improved arterial blood flow (Figure 5B and S4B),
and preserved cerebral oxygen tension (Figure 5C) 2 h after reperfusion
compared to the vehicle-treated and sham control groups. Our data
indicate that itaconate prevents cerebral vasoconstriction during
reperfusion, which preserves cerebral blood flow and oxygen supply
critical for tissue oxygenation and function. Cerebral vasospasm is an
important cause of morbidity during ischemia reperfusion that is
independently associated with reduced instrumental activities of daily
living, cognitive impairment, and poor quality of life [44]. Importantly,
itaconate’s effects on blood flow-mediated oxygenation and nutrient
supply were as effective as emergent endovascular spasmolysis and
vasodilators [45].
We next sought to determine whether itaconate reduces inflammation
associated with reperfusion in vivo. Reperfusion induces an inflam-
matory response impacting brain edema formation. Comparison of the
sham and vehicle groups demonstrated that ischemia-reperfusion
injury increased brain edema by 4.7%. Itaconate administration
significantly mitigated this increase to 1.8% such that the itaconate
cohort was not different than the sham group (Figure 5D). Reperfusion
increases leukocyte-endothelial adhesion, a hallmark of neural
inflammation. Therefore, we quantified leukocyte adhesion to the
vascular endothelium at baseline and 2 h post-reperfusion using our
mouse cranial window chamber model. Supplementation of itaconate
in reperfusion fluid significantly decreased the number of rollingaccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 129
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Original Articleleukocytes after 2 h, providing additional evidence that itaconate
reduced inflammation relative to the vehicle-treated control conditions
(Figure 5E). Importantly, leukocyte-endothelial adhesion is regulated by
inflammatory adhesion molecules, which are regulated by oxidative
stress. Oxidative stress can regulate the expression of endothelial cell
adhesion molecules (CAMs) by a direct activation of CAMs and tran-
scription factors (that is, NF-kB and AP-1). In addition to oxidative
stress, inflammatory mediators such as thrombin, VEGF, IL-17, and
TNF-a are known to enhance the surface expression of CAM P-selectin
to mediate leukocyte adhesion [46]. Therefore, our data suggest an
important role for itaconate in decreasing redox stress, inflammation,
and leukocyte-endothelial interaction associated with ischemia-
reperfusion injuries.
Given the positive effects of itaconate on metabolism, hemodynamics,
and inflammation, we next tested whether itaconate affects overall
brain function and quantified neurological behavior following ischemia130 MOLECULAR METABOLISM 32 (2020) 122e135  2019 The Authors. Published by Elsevier GmbH. Tand reperfusion. While reperfusion significantly decreased motor and
behavioral function in the vehicle compared to the sham groups, the
itaconate-treated group was not significantly different from the sham
animals (Figure 5F). Collectively, these results provide evidence that
itaconate protects the brain against reperfusion injury by influencing
redox metabolism, blood flow, and oxygen delivery, reducing inflam-
mation and improving overall brain function in a mouse model of neural
ischemia-reperfusion injury. These promising pre-clinical data warrant
further investigation in additional animal models and species along
with an evaluation of the therapeutic window.
3.6. Itaconate reduces mortality from TBI with hemorrhagic shock
To assess whether itaconate mitigates more severe cerebral reper-
fusion injuries, we examined the physiological benefits of itaconate
when supplemented to resuscitation fluids used to treat TBI followed
by hemorrhagic shock resuscitation. The immediate goal of currenthis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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maintain consciousness and central nervous system activity. We used
a mouse model of fluid percussion TBI followed by 50% of the animal’s
blood volume hemorrhage that resulted in a decrease in the mean
arterial pressure (MAP) to 35e40 mmHg (Figure 6A). We then provided
volume fluid resuscitation to maintain MAP above 70 mmHg usingBA
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tend, or Hextend supplemented with 15 mg/mL of water-soluble
itaconate. The MAP was not affected by the choice of resuscitation
fluid (Figure 6A). Notably, inclusion of itaconate slightly reduced the
total resuscitation volume required to preserve the MAP compared to
the control group with Hextend alone, suggesting that itaconate mayC
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Original Articledecrease the dilution of clotting factors in the blood, reducing the risk
of additional hemorrhage (Figure 6B). Finally, itaconate significantly
increased survival rates 7 days after reperfusion compared to the
control group (66.7% vs 16.7% survival), indicating that itaconate
impacts physiology to improve overall outcomes in reperfusion injuries
(Figure 6C). These data correlate with evidence of increased tissue
oxygenation, reperfusion, and metabolic recovery in animal models of
trauma and metabolic reprogramming in cultured neurons, supporting
the concept that itaconate improves physiological outcomes associated
with reperfusion injury.
4. DISCUSSION
In this study, we demonstrated that inclusion of itaconate in resusci-
tation fluids limits reperfusion-induced injurious metabolic processes.
Our findings integrate distinct physiological benefits in animal models
with molecular analysis in cultured brain cells, highlighting the regu-
lation of metabolic pathways and anti-oxidant response by itaconate.
Cerebral ischemic conditions limit nutrient and oxygen supply for brain
metabolism, impacting numerous biochemical pathways. Reperfusion
of ischemic tissue drives the production of mitochondrial superoxide
[47e51]. For example, high levels of succinate have been detected in
multiple tissues under ischemic conditions, and after reperfusion, this
accumulated succinate is rapidly oxidized by SDH, resulting in
increased mitochondrial ROS production and damage [4,5,52]. In this
study, we demonstrated that itaconate decreases SDH activity in brain
cells (Figure 1D) and reduces ROS/RNS levels upon reperfusion in vivo
(Figure 4I), suggesting that targeting this enzyme complex may buffer
against the oxidative damage that occurs under such conditions. The
first few minutes of reperfusion are critical as they initiate long-term
tissue damage and dysfunction [1]. Inhibitors of SDH, that is,
dimethyl malonate and atpenin A5, have been shown to ameliorate
reperfusion injuries in a variety of in vivo models [5,53,54]. Importantly,
in our current study, the respiratory chain remained partially inhibited
upon itaconate infusion during reperfusion, and itaconate-dependent
regulation of SDH activity resulted in a gradual “awakening” of mito-
chondrial metabolism after reperfusion. Thus, itaconate may inhibit
mitochondrial superoxide formation by slowing (but not halting) the
reintroduction of electrons into the mitochondrial electron transport
chain upon reperfusion [51]. Importantly, our data indicate that itac-
onate is cleared from the plasma within 24 h after reperfusion
(Figure 4B), which should permit full recovery of SDH activity and
respiratory function that is important for recovery after such injuries.
To neutralize free oxygen radicals during reperfusion, cells activate
anti-oxidant responses. Nrf2 is a transcription factor of the endogenous
anti-oxidant response and is recognized as a regulator of cellular
metabolism to fulfill the increased cellular glutamate demand for
glutathione synthesis [38e40,55,56]. In our study, itaconate promoted
redox metabolism and reprogrammed glutamine metabolism in vitro
and in vivo. Since itaconate increased glutamine use in the TCA cycle
in the cultured neurons, this molecule could promote the oxidation of
alternate substrates during reperfusion when glucose availability is
limited. Itaconate significantly reduced inflammation-induced brain
damage and increased neurological function, which may be attributed
to the regulation of neuronal anti-oxidant response and SDH inhibition
induced by exogenous itaconate. In addition, carboxylic acids, such as
pyruvate, are effective ROS scavengers [57] and therefore itaconate
itself may function as an endogenous anti-oxidant molecule limiting
the cytopathic effects of reduced forms of oxygen. Thus, itaconate-
dependent metabolic regulation could mitigate reperfusion injuries or
benefit other diseases driven by oxidative stress.132 MOLECULAR METABOLISM 32 (2020) 122e135  2019 The Authors. Published by Elsevier GmbH. TWe observed that plasma itaconate cleared within 24 h, suggesting
that it is readily metabolized in vivo (Figure 4B). Thus, itaconate and/or
its degradation products may also affect the metabolic function of
diverse cell types and tissues. The liver is likely the primary site of
itaconate degradation, which occurs via activation to itaconyl-CoA and
further breakdown into pyruvate and acetyl-CoA, and this metabolic
process has been observed in isolated liver mitochondria [58]. How-
ever, our tracer study indicated that the cultured brain cells did not
catabolize itaconate into TCA cycle intermediates in detectable
amounts, similar to macrophages and cancer cells [16]. Alternatively,
itaconate might be secreted in urine as observed in dogs and rats
[59,60]. Itaconate and its potential metabolic products are likely to alter
cellular function in multiple organs at a system level to limit the
pathological consequences of diseases. For instance, since itaconate
reduced ROS/RNS levels (Figure 4I) and prevented collapse of blood
vessels in our in vivo animal model (Figure 5B), itaconate might also
reprogram endothelial metabolism and affect nitric oxide synthase
(NOS) expression and/or nitric oxide (NO) production to promote further
protection in ischemia reperfusion.
The immediate goals of treating brain injuries are optimizing cerebral
blood flow and oxygenation, minimizing intracranial pressure fluctu-
ations, and reducing cerebral edema [6]. However, intravenous infu-
sion of fluids (colloids and crystalloids) dilutes clotting factors causing
additional injury [61]. Our data indicate that itaconate reduces the
extent of tissue damage caused by ischemia and TBI/hemorrhagic
shock, the resulting oxygen insufficiency, and the adverse conse-
quences of reperfusion injury; all of which are characterized by the
development of both localized and systemic oxidative stress driving cell
death. Further, our results suggest that itaconate may add cellular
protection to the fluid resuscitation strategy to maintain body function,
thereby improving outcomes. Thus, itaconate is a central factor to
mitigate reperfusion-induced injuries and a target for intervention.
Our results indicate considerable promise for the translation of an
itaconate-based treatment strategy to mitigate reperfusion injuries, yet
there are several limitations to our study. All of the intervention studies
were conducted in male mouse models, and the potential translational
relevance of itaconate in humans requires formal testing in a time- and
dose-dependent manner. Human CAD/IRG1 is less active than the
murine enzyme, in part due to naturally occurring mutations [21].
Deficiency of CLYBL enzyme impairs itaconate degradation and im-
pacts B12 metabolism [36]. These changes could influence the ability
of patients to safely process itaconate. Thus, factors such as sex and
genetic background must also be considered in future studies. Indeed,
the impact of exogenous itaconate may differ by sex as macrophages
from estrogen-deficient mice synthesize less endogenous itaconate
than wild-type mice [62]. Notably, itaconate was administered prior to
initiating ischemic injury (and reperfusion) in our mouse model of IR
rather than after the primary injury occurred. However, we adminis-
tered itaconate after the primary injury and during reperfusion in our
model of TBI/HS supporting the hypothesis that the Nrf2 pre-
conditioning effect might not be the key phenotypic driver. Rather, our
results support the concept that rapid SDH inhibition might be most
effective for protection. Future studies will explore itaconate admin-
istration scheduling and propose strategies in more detail. However,
itaconate is a natural molecule that has a long shelf life and is soluble.
SDH activity has emerged as a focal point of investigation for diverse
metabolic diseases beyond reperfusion injuries, including cancer
[63,64], neurodegeneration [65], and inflammation [16,17,66]. Since
itaconate impairs SDH activity in a number of different cell types
[16,17,67], itaconate may accelerate important progress in clinical
medicine. However, since itaconate has only recently been describedhis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
as an endogenous metabolite, we are still beginning to understand its
functional impacts in different cell types.
5. CONCLUSIONS
Collectively, our study supports continued research in this area and
demonstrates that exogenous itaconate favorably modifies the host
response to ischemia and reperfusion that is sufficient to suppress
reperfusion-related injuries. These are the first studies of exogenous
itaconate treatment that could be an important new strategy to in-
crease intracellular itaconate levels in vital organs to improve
metabolic homeostasis in ischemia and reperfusion. We believe that
our results might add significantly to the current understanding of
the clinical experience with identification and verification of thera-
peutic efficacy of a new itaconate-based treatment strategy to
reduce cellular injuries in the response to ischemia and re-
oxygenation.
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